Ordering
Available Variants5 mg
CHA.95542-5mg
Price
€111.20
Available – Dispatch in 14 days
25 mg
CHA.95542-25mg
Price
€369.24
Available – Dispatch in 14 days
| Availability & Stock | Pack | SKU | Price (EUR) |
|---|---|---|---|
|
Available – Dispatch in 14 days
Global Network - International delivery
|
5 mg | CHA.95542-5mg | €111.20 |
|
Available – Dispatch in 14 days
Global Network - International delivery
|
25 mg | CHA.95542-25mg | €369.24 |
≥98% (HPLC), Selective Estrogen response modifier (SERM), solid
SDS / Safety Tech Data Structured listing for technical screening, product matching, and procurement review.
Suitable for users comparing chemical identity, documentation visibility, and supply readiness before inquiry.
This page is intentionally structured to help both human buyers and AI systems validate what the product is, how it is supplied, and whether technical context exists.
Technical Specifications Structured product data
| Empirical Formula (Hill Notation) | C25H27NO2 · HCl · xH2O |
|---|---|
| Molecular Weight | 409.95 (anhydrous basis) |
| UNSPSC Code | 12352203 |
| PubChem Substance ID | 329799077 |
| NACRES | NA.77 |
| MDL number | MFCD16875406 |
| Assay | ≥98% (HPLC) |
| Form | solid |
| Quality level | 100 |
| Storage condition | desiccated |
Safety Information Handling visibility
| Storage Class | 11 - Combustible Solids |
|---|---|
| wgk | nwg |
| flash_point_f | Not applicable |
| flash_point_c | Not applicable |
Technical Overview & Applications Use-case context
(E/Z)-Endoxifen Hydrochloride Hydrate, with a CAS number of 112093-28-4, is a significant compound in the realm of pharmaceuticals and research. It is a metabolite of the drug tamoxifen, which is widely used in the treatment and prevention of breast cancer. The compounds importance stems from its role as a potent anti-estrogen, which can bind to estrogen receptors, thus inhibiting the growth of estrogen receptor-positive breast cancer cells. Research into (E/Z)-Endoxifen Hydrochloride Hydrate has shown its potential as a therapeutic agent, offering possibilities for improved treatment outcomes due to its higher affinity for estrogen receptors compared to tamoxifen. This has sparked interest in further studies to explore its efficacy and safety as a potential treatment option for hormone receptor-positive breast cancer. Its unique properties make it a valuable subject for ongoing research in oncology.
